SEMICONDUCTOR

HEALTHCARE
ATTHE
AT THEFRONTIER
FRONTIER IN
IN
A CORONAVIRUS WORLD
A CORONAVIRUS WORLD

Insights
Insightsfor
forHealthcare
HealthcareCXOs
CXOstotoGauge
GaugeThe
TheImpact
Impact
ofofShort
ShortTerm
TermChanges
Changeswith
withTheir
TheirClients’
Clients’Clients
Clients
© 2020 MARKETSANDMARKETS | WWW.MARKETSANDMARKETS.COM
CORONA VIRUS PANDEMIC - EXTRAORDINARY TIMES CALL FOR EXTRAORDINARY MEASURES

The World is fighting the Novel Corona Virus Disease 2019 (COVID 19)
health pandemic. No one ever needed healthcare experts more than
now! Despite having no prior experience with virus as resilient as
COVID19, Healthcare experts have stepped up and put their lives at
stake to serve the Mankind. Their sincere intent for saving lives and
humanity has won them immense trust and respect! We salute all the
Healthcare Experts. Truly inspirational.
Every company has created war rooms to fight this situation. They have
no idea how other similar companies are thinking and taking next steps;
how their clients are changing priorities, reducing their spends in some
and increasing investments in other specific areas, shifting product
lines, addressing blind spots in their supply chain, and how their
ecosystem is rapidly getting impacted across geographies and several
sectors!

There is similar war being fought in parallel ─ the Economic pandemic! This is a dual war ─ with the healthcare pandemic and the economic
Caused by complete lockdown across hundreds of countries to beat pandemic!
COVID 19, CXO’s worldwide in every company are fighting the Economic
pandemic. The magnitude of this pandemic is in Trillions of Dollars!

© 2020 MarketsandMarkets | www.marketsandmarkets.com 2

CASCADING IMPACT OF SHORT TERM PRIORITIES ACROSS YOUR ECOSYSTEM WILL IMPACT YOUR REVENUE CHOICES

At MarketsandMarkets, we have committed ourselves to support businesses to survive this

pandemic, no matter what! We all need to fight this dual war-healthcare pandemic and
economic pandemic to help companies sustain!

Our 1,000 analysts and experts are working day and night, engaging all stakeholders of
client companies ─ their clients, their clients’ clients and vendors to find rapid shifts and
unprecedented decisions being taken by CXOs and making this available to all board
rooms swiftly to help them sustain the economic pandemic, and enable survival of their
companies with right choices!

It is insights from this work that we are now bringing to you as a series of CXO Decks across
vertical domains. This CXO slide deck will help Healthcare CXOs to gauge the impact of
short term changes with their clients’ clients.

Hope you find these insights useful. If you require any additional insights, or would like to
get into a free workshop to contextualize our insights for you, please feel free to call us on
+1-888-600-6441 (US)/ +44-800-368-9399 or write to us on
info@marketsandmarkets.com

Above all, please stay safe and keep your community safe with social distancing. Wishing
you the best!

Sandeep Sugla
CEO, MarketsandMarkets

© 2020 MarketsandMarkets | www.marketsandmarkets.com 3

COVID -19’S PACE OF GLOBAL PROPAGATION IS UNPRECEDENTED**

The true number of infected people is probably higher than the official total, as some mild and asymptomatic
cases are likely not tested and counted **Data as of
1,048
5,018
March 22, 2020
21,463
233
13
81,499 8,897
67
14,296 UK 21,638
Canada 104
15,219
Germany 3,267
562 France 1,685
Republic 1,046
201 China of Korea
US 24,926
164 Spain Italy Iran
341 36
Japan
294,110
53,578
1 1,326
5
4,827 India
GLOBAL CONFIRMED CASES Mexico
915

12,944 40
Africa
TOTAL DEATHS
No. of
Positive

186 Cases
No. of
COUNTRIES/TERRITORIES Death Propagation Limited Ongoing Ongoing Mature Decline
/AREAS AFFECTED
Source: WHO (World Health Organization) Coronavirus Disease 2019; data as of March 22, 2020. Graph is not to scale. Numbers are actual reported cases.

© 2020 MarketsandMarkets | www.marketsandmarkets.com 4

MOST COUNTRIES ARE LIKELY TO HAVE NEGATIVE IMPACT ON GDP GROWTH

ILLUSTRATIVE CORONAVIRUS SCENARIOS HIGHLIGHT THE ADVERSE IMPACT ON GROWTH

China Other Asia Pacific G20 North America World Commodity Exporters Europe
0.0
Change in GDP growth in 2020 relative to baseline (%)

-0.2

-0.4

-0.6

-0.8

-1.0

-1.2

-1.4

-1.6

-1.8

-2.0 Base-case Scenario Broader Contagion Scenario

Source: OECD Interim Economic Assessment Coronavirus: The world economy at risk March 2, 2020; Accessed on March 18, 2020

© 2020 MarketsandMarkets | www.marketsandmarkets.com 5

3 POSSIBLE SCENARIOS IN TERMS OF IMPACT ON THE GLOBAL ECONOMY
SCENARIO /
CRITERIA
No. of countries reporting cases
No. of countries in pandemic
stage (Phase 4 & above –
Community level outbreaks):
Public health action and
response
No. of countries under lockdown
and duration of lockdown
Dip in economic activities
Recovery period
WILD PROGRESSION WITH GLOBAL
RECESSION (PESSIMISTIC)
All 195 reporting positive cases
Top 20 economies in stage 4 & above
Widespread local transmission result in
collapse of healthcare systems globally
with limited capacity to attend the
masses of critically ill patients
More than 100 countries, with more than
12 months lockdown
Effect on the global economy to the tune
of USD9.2 trillion. British and US
economy shrink by 4.2% and 8.4%
respectively by the end of 2020.
Recovery expected to be gradual through
2021 & Severe negative impact on
employment rates
© 2020 MarketsandMarkets | www.marketsandmarkets.com
MODERATE PROGRESSION AND GLOBAL
ECONOMIC SLOWDOWN (REALISITC)
Less than 195 countries but more than 150
countries reporting positive case
Less than top 20 and more than top 10
economies in stage 4 & above
Social distancing and quarantine show limited
success, with increased local transmission and
domestic spread due to lack of enforcement.
Between 100 to 50 countries under lockdown for
6 to 9 months
Global economic impact — affecting Asia, Africa,
and the Middle East. The EU proposes increasing
liquidity to at least 10% of GDP
Drop in confidence and supply chain disruption to
intensify impact. Dip in manufacturing activities
and employment.
MILD PROGRESSION WITH SHORT-TERM
IMPACT (OPTIMISTIC)
Less than 100 countries reporting
positive cases
Less than top 10 economies in stage 4 &
above
Successful control of domestic spread
and local transmission through rapid
response, isolation of the sick, social
distancing
Less than 50 countries under lockdown
for 3 to 6 months
British and US economy falls by 1.5% and
2% respectively. US unemployment rate
soars to 5% due to lockdowns, but
gradually recovers by December 2020
Initial dip in worldwide consumer demand
to bounce back quickly and stabilize over
time.
6
IMPACT OF COVID-19 ON HEALTHCARE – WILL THE CURRENT SITUATION
BE PROFITABLE FOR COMPANIES OPERATING IN VARIOUS SUB-DOMAIN OF HEALTHCARE?

The COVID-19 outbreak is severely impacting global markets and businesses across sectors and industries, forcing companies to actively plan for sustainability instead of
continuing with their growth strategies. This outbreak is also forcing companies to look at various opportunities for sustainability and business continuity

HIGH IMPACT OF COVID-19 ON INDUSTRY/SECTOR LOW

MEDICAL DEVICES DIAGNOSTICS INFECTION CONTROL HEALTHCARE IT PHARMA & BIOTECHNOLOGY

▪ Medical Devices manufacturers, ▪ Development of new diagnostic ▪ High demand of Masks, PPEs, ▪ Demand for IoT, mHealth, ▪ API supply disruption due to
especially IR Temperature tests for COVID-19 and approval Sanitizers, surface disinfectants Telehealth, Remote Patient lockdown in China & Italy
How the sectors are impacted?

monitoring devices, ventilators
will see sudden increase in
demand
▪ Demand for other Medical
devices, such as CT Scanners
and hospital beds, will also see
increasing demands
▪ Manufacturing schedules will be
delayed due to lockdown
situation
will be faster
▪ Current fields of diagnostic tests
such as PCR will show increased
reagents and equipment
demands
▪ Supply may take a temporary hit
and will have irregular supply
due to public response to
healthcare authorities
▪ Shortage of supplies and sudden
increase in the prices
Monitoring , Virtual care, and
healthcare at home will go up
significantly.
▪ Adoption of digital and virtual
platforms will increase
▪ Drug supply shortage due to
manufacturing lockdowns and
unavailability of APIs
▪ Contract Manufacturing
Organization will face challenges
for short to mid term duration
▪ Surge in new drug discovery and
vaccines development for the
treatment of COVID-19
▪ Ongoing clinical trials of drugs
apart from COVID-19 will take a
backseat; potential delay in
launching new drugs for other
indications.
▪ Clinical Research Organizations
will get fewer number of projects

Source: MarketsandMarkets analysis

© 2020 MarketsandMarkets | www.marketsandmarkets.com 7

MEDICAL DEVICES, DIAGNOSTICS, INFECTION CONTROL, AND HEALTHCARE IT SECTORS WILL SHOW GAINS; WHILE
PHARMA, BIOTECH AND CLINICAL RESEARCH WILL SEE MODERATE GROWTH IF NOT DIRECTLY INVOLVED IN COVID-19
MEDICAL DEVICES
IMPACT OF COVID-19 IN THE TECHNOLOGY SPACE
▪ Surge in the number of
patients will drive
demand for various
medical devices namely
medical beds,
ventilators,
thermometers, multi-
parameter monitors and
thermometers
▪ Countries like the US,
Italy, Spain, and Iran will
register shortage of
these devices
nationwide
▪ Medtronic, Hamilton,
ResMed, and other
players will have to
ramp-up capacities to
make ventilators
available
▪ This demand will last for
the next three-four
quarters
Significantly
Positive Impact
Source: MarketsandMarkets analysis
DIAGNOSTICS INFECTION CONTROL HEALTHCARE IT PHARMA & BIOTECH CLINICAL RESEARCH
▪ Roche and Thermo ▪ Usage of disinfectants ▪ Healthcare IT will play a ▪ Drug Repurposing: 31 ▪ In pandemic countries
Fisher collectively have and masks has surged. crucial role in providing existing drugs have been which are clinical
nearly 2 million tests Many regulatory treatment to other identified as potential research hot spot,
available, with more to authorities are diseases when drug candidates for hospitals and
come for screening expanding the list of healthcare facilities are COVID-19 investigators are
COVID -19 approved disinfectants affected by the high ▪ Around 10 vaccines are overwhelmed by COVID-
▪ Many key POC ▪ Many large, mid-sized, COVID -19 patient load under various phases of 19 patients, and, as a
companies such as and small companies and must prioritize development consequence, have to
Cepheid, Mesa Biotec will ramp-up capacities COVID-19 patients over ▪ New drug or Vaccine deprioritize ongoing
are investing in to cater to sudden spike other diseases against COVID-19 will be trials.
developing rapid in demand ▪ To reach out to available latest by 2021 ▪ Clinical Research and
coronavirus testing ▪ This demand will physicians, pharma ▪ 80% of API required for new product launches for
▪ Some companies such continue for the next six- companies will adopt US pharmaceutical other indications will be
as Randox Laboratories nine months and digital and virtual manufacturing is delayed significantly
and Credo diagnostics decline platform to ensure imported from India and ▪ Some of the pharma &
have already developed business continuity China biotech companies are
POC test during restricted access ▪ Countries apart from likely to stop or withdraw
to Medical Reps China, Italy & India that ongoing trials for two-
▪ Benefits for diagnostic
▪ Healthcare IT will have can supply APIs will three quarters
companies over the next
sustained demand post garner market shares ▪ E-clinical trials likely to
three to four quarters
COVID-19, reliance on from existing suppliers see increased adoption
HCIT technology will
become a routine
Moderately Moderately Moderately Moderately Moderately
Positive Impact Positive Impact Positive Impact Positive Impact Negative Impact
© 2020 MarketsandMarkets | www.marketsandmarkets.com 8
 IN VITRO DIAGNOSTICS
COVID-19 IMPACT ANALYSIS

© 2020 MARKETSANDMARKETS | WWW.MARKETSANDMARKETS.COM

© 2020 MarketsandMarkets | www.marketsandmarkets.com 9

IMPACT OF COVID-19 PANDEMIC ON ENTIRE IVD ECOSYSTEM- KEY HOT SPOTS OF ACTIVITIES GAINING MOMENTUM

Technology Instrumentation Reagents & Services Indication Application End Users

ELISA Lateral Flow Targeted Resequencing

Immunoassay/Imm

CROs
unochemistry Diabetes
Radioimmunoassay Western Blot RNA Sequencing
▪ Tissue Diagnostics

Home Care
Immunohistochemistry Immunofluorescence ▪ Companion
Chip Sequencing

Lab Services
Infectious Disease Diagnostics
Clinical Chemistry Immunoprecipitation Spectroscopy ▪ Precision Medicine
Whole Genome Sequencing
Core Technologies

▪ Quality Control &

Pharmaceutical
Flow Cytometry Chromatography Process Validation

Companies
& Biotech
Exome Sequencing Oncology/Cancer
Next-Generation
Nanopore Sequencing
Sequencing

End Users
Molecular De Novo Sequencing
Electrophoresis RT-PCR Cardiology
Diagnostics
▪ Biomarker

Academic &
Nucleic Acid Extraction Calibrators

Institutes
Research
Microarray and Purification Discovery
▪ Disease Diagnosis
MDx Reagents Nephrology ▪ Drug Testing/
Clinical Coagulation &

Reagents
Hematology Pharmacogenomis
Microbiology Hemostasis Hematology Reagents ▪ Proteomics

Hospitals/
Clinics
Autoimmune Diseases ▪ Genomics
Microbiology Reagents ▪ Drug Discovery
Hand Held Devices Analyzers Rapid Test Kits
Instruments

▪ Prognostics
▪ POC Testing
QC Reagents
HIV/AIDS ▪ Multiplex assays

Labs
Home Care Devices POC Devices Immunoassay
Reagents

Immediate Impact Impact in next 5-6 months No Impact Source: MarketsandMarkets analysis

© 2020 MarketsandMarkets | www.marketsandmarkets.com 10

 TO CONTROL WILD PROGRESSION OF COVID-19 - THE KEY LIES IN EARLY DETECTION AND ISOLATION USING RAPID
TESTING SOLUTIONS

SURGE IN DEMAND FOR TESTING Countries such as Singapore, Taiwan and Hong Kong
▪ With recent exponential rise of COVID- 19 cases in countries such as China, US, and Italy, the world has now understood the have showed limited impact despite their proximity to
importance of testing and increased testing capabilities. There are many tests available in the market, but the need of the hour is a China.
more accurate diagnostic solution to reduce the spread of Covid-19 coronavirus.
▪ A Shift is now visible in testing regime, from centralized lab-based testing-that took days to provide results-to POC-based tests. Many The three regions have managed to keep case numbers
regulatory authorities have implemented rapid COVID-19 testing guidelines including, including USFDA, and approving tests under
Emergency Use Authorization (EUA). This is resulting in emergence of new tools using POC diagnostics.
and fatalities low by rapidly deploying widespread
▪ For example, Cepheid’s rapid POC test was recently approved by the USFDA; this development paves the way for more rapid POC
testing, combined with digital surveillance to trace
tests. Other countries are also focusing on rapid POC testing. individuals’ movements, and impose strict quarantines
in suspect cases.

CENTRALIZED LAB TESTING RAPID POINT OF CARE TESTING Roche Diagnostics, Thermo Fisher Scientific, Qiagen
(soon to be acquired by Thermo Fisher) and Quest
TAKES FEW DAYS TAKES FEW HOURS Diagnostics are ramping up the capacity to perform
tests by rolling out automated SARS-CoV-2 testing
systems and services.
TESTING SERVICES

▪ Some private companies, including Lab Corp and Quest Diagnostics, have started offering testing services for the virus already, in CURRENT EUA LANDSCAPE
addition to state and hospital labs. The participation of the private sector is likely to provide better commercial opportunities as well FOR COMMERCIAL TESTING
as faster disease control in various countries.
▪ These include Instrument-agnostic test kits and tests
SUPPLY CHAIN that run on a designated test system or instrument.
▪ Five of the assays that have been granted EUA—from
▪ The spread of COVID-19 has exposed major gaps in the abilities of most countries to respond to a virulent new pathogen, especially
from the standpoint of raw materials. The unavailability of reagents has been a key factor limiting the mass distribution of COVID-19
Roche, Hologic, Abbott, GenMark, and DiaSorin
tests. Molecular—can only be run on those companies' test
▪ To fulfill the increasing demand suppliers of testing materials have also ramped up production. Companies such as Promega systems, while two other test kits—from Thermo
Corporation are helping supply materials used in COVID-19 diagnostic tests. Fisher Scientific and Quidel – can potentially run on
other PCR systems.

© 2020 MarketsandMarkets | www.marketsandmarkets.com 11

FOR SUSTAINED MARKET SUCCESS, STRATEGY OF INVESTING & INNOVATING IN “THE NEW” NEEDS AND CONTINUOUS
REALIGNMENT WITH EVER EVOLVING CLIENT IMPERATIVES IS THE KEY

IN VITRO DIAGNOSTICS MARKET CLIENTS/PROSPECTS HOT BETS END USER

Revenue Mix Future* Revenue Mix Labs

(Pre COVID 19 market scenario) (Next 6 months-2 years) RT PCR

▪ Abbott
Old Laboratories Hospital/Clinics
Sources ▪ Becton, Dickinson &
New Use Case Company
Old New Technologies/Dressings ▪ Biomérieux
Sources New New Ecosystem Market ▪ Bio-Rad
Sources New Product/Offering New Sources Laboratories
New Client/Partners/Target M&A Immunoassay Academic
▪ Danaher
▪ F. Hoffman-La Lateral Flow Research
* Likely revenue mix Roche Ltd. INFECTIOUS Institutes
▪ Merck KGaA DISEASES
▪ Qiagen
Pharmaceutical
▪ Oncology/Cancer Diagnostics ▪ Thermo Fisher
Bioinformatics Biotech
▪ Precision Medicine Scientific
▪ Infectious Disease ▪ Oncology/Cancer ▪ Illumina, Inc. Companies
▪ Biomarker Discovery
Diagnostics Diagnostics ▪ Agilent
▪ Sequencing
▪ RT-PCR ▪ Precision Medicine Technologies, Inc.
▪ POC
▪ Immunoassay ▪ Biomarker Discovery CROs
(Lateral Flow) ▪ Sequencing
Sequencing
▪ Rapid Tests ▪ POC
Home Care

▪ With the advancement of high-throughput

▪ Due to the surge in the number of patients, demand has grown ▪ Rapid tests provide results within hours. There will be high usage of
genomic technologies, companies primarily
exponentially for diagnostic tests. For now, more than 50 companies have qPCR (RT PCR) in COVID-19 diagnosis, which will result in high growth
focused on the identification and development of
launched clinical tests based on Immunoassay and RT-PCR. Companies in the next two to three quarters.
novel biomarkers in Oncology.
have also introduced rapid tests in both categories.
▪ Oncology was ultimately a high revenue-
▪ Oncology will witness slower growth, as companies are prioritizing COVID ▪ Sequencing will witness growth in next 5-6 months, as companies are
generating pocket. Other indications such as
19 solutions. Healthcare providers have alsochanged priorities still finding major application of NGS based tests in research
infectious diseases were of lesser priority.

© 2020 MarketsandMarkets | www.marketsandmarkets.com 12

 INFECTION
CONTROL MARKET
COVID-19 IMPACT ANALYSIS

© 2020 MARKETSANDMARKETS | WWW.MARKETSANDMARKETS.COM

© 2020 MarketsandMarkets | www.marketsandmarkets.com 13

IMPACT OF COVID-19 PANDEMIC ON INFECTION CONTROL ECOSYSTEM- KEY HOT SPOTS OF ACTIVITY GAINING
MOMENTUM

CATEGORIES PRODUCTS END USERS

DISINFECTION TECHNOLOGIES
HOSPITALS & CLINICS
INFECTION CONTROLL & STERILIZATION TECHNOLOGIES

Disinfectants Instrument Disinfectants Hand Disinfectants Skin Disinfectants Surface Disinfectants

Disinfectors Washer Disinfectors Flusher Disinfectors UV Ray Disinfectors Ultrasonic Cleaners

MEDICAL DEVICE COMPANIES
Medical Nonwovens Surgical Drapes Gowns Sterilization Wraps Face Masks

Endoscope Reprocessing Automated Endoscope Endoscope Tracking Endoscope Reprocessing

Products Reprocessors Systems Consumables
FOOD & BEVERAGE INDUSTRY
STERILIZATION TECHNOLOGIES

Moist Heat Sterilizers
Sterilizers
Formaldehyde Sterilizers
Dry Heat Sterilizers
Radiation Sterilization
Equipment
Hydrogen Peroxide
Ethylene Oxide Sterilizers PHARMA & BIOPHARMA
Sterilizers
MANUFACTURERS
Filtration Sterilization
Equipment

Sterilization Consumables Chemical Indicators Biological Indicators Packaging Accessories RESEARCH ORGANIZATIONS,
ACADEMIC INSTITUTES, CONTRACT
Sterilization Services Ethylene Oxide Gamma E-Beam Steam MANUFACTURERS, LABORATORIES

GROWTH% IN 2020 KEY AERA OF IMPACT GROWTH% IN 2020 KEY AERA OF IMPACT GROWTH% IN 2020 KEY AERA OF IMPACT

Disinfectants (Hand, Face Hospitals and

Skin, & Surface) Mask Clinics

No COVID-19 Next two quarter Next 6-12 Months Average High High to Moderate

© 2020 MarketsandMarkets | www.marketsandmarkets.com 14

BOTH MARKET & TECHNOLOGY LANDSCAPE IS GETTING IMPACTED DUE TO COVID-19 PANDEMIC

▪ The emergence of the COVID-19 pandemic has resulted in unprecedented demand of product segments such as hand disinfectants, skin
disinfectants, and surface disinfectants. These product segments and disposables are expected to be significant revenue drivers for several
manufacturers in the next two quarters to two years.
▪ Governments across the globe are providing funds for medical devices and disposables required to cater to the sudden increase in infected
patients. This has increased pressure on the stakeholders of the medical devices industry to strengthen their existing manufacturing capabilities
and supply chains
▪ There is a resultant high demand for other personal protective equipment and gear like masks, aprons, gloves and hazmat suits. In response,
existing players in the market, along with new entrants, are working to strengthen their position in the respective markets.
• On March 20, 2020, Beiersdorf started the serial production of medical-grade disinfectants to support the fight against the coronavirus pandemic
in Europe. This is a leading example of repurposing of production line to support critical-need products.
• In February 2020, Lanxess, a Germany-based specialty chemicals company with strong biocidal technology capabilities, came out with a high-level
disinfectant, Rely+On Virkon, which is considered effective against the coronavirus.
• In an interesting development of a novel technology emerging on the market landscape, Sisak Company started promoting an Ozone-based
surface disinfectant which unique advantage of not leaving any chemical residue on the surface.
• Anabec Systems, Anasphere, which works by destabilizing membrane of Virus cell, is considered a major breakthrough in inhibiting the spread of
covid-19. it recently received EPA clearance on March 19, 2020 and is expected to emerge as a major weapon to fight the pandemic.

© 2020 MarketsandMarkets | www.marketsandmarkets.com 15

MARKETSANDMARKETS™ – THE WORLD’S LARGEST REVENUE ADVISORY FIRM

MARKETSANDMARKETS™ IS THE WORLD'S LARGEST

REVENUE IMPACT ADVISORY FIRM HAVING IMPACTED OVER USD 5.6 BN IN NEW REVENUES
HIGH LOW
Join the 7,500 companies worldwide, including 80% of the Fortune 2000 companies, who engage our robust advisory and
KnowledgeStore™ market intelligence platform to make high impact revenue decisions amidst shift in revenue sources and
creation of unknown unknowns due to inter-connected adjacencies (direct or indirect) of their Clients, Clients' clients, Vendors, and
Vendors' vendors.

KEY DIFFERENTIATORS
▪ Quantified B2B research on 30,000 high growth niche opportunities/threats which impact 70% to 80% of worldwide companies'
revenues (10 years of research by 1000 analysts)
▪ Almost 75,000 top officers across eight industries worldwide approach us for their pain points around revenues decisions.
▪ Our 1,000 fulltime analyst and SMEs track global high growth markets following the "Growth Engagement Model - GEM". The GEM
aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack,
avoid and defend" strategies and identify sources of incremental revenues for both the company and its competitors.
▪ Flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire
value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
▪ Unique lens of analysing interconnected ecosystems makes us uniquely positioned to understand the revenue shifts and impact
of COVID-19 to assist our clients in this unprecedented pandemic catastrophe

© 2020 MarketsandMarkets | www.marketsandmarkets.com 16

Copyright © 2020 MarketsandMarkets™

All Rights Reserved. This document contains highly confidential information and is the sole property of MarketsandMarkets™. No part of it shall be circulated, copied, quoted, or otherwise reproduced without the prior written approval of
MarketsandMarkets™.

DISCLAIMER
MarketsandMarkets™ provides strategic analysis services to a select group of customers in response to orders. Our customers acknowledge when ordering that these strategic analysis services are solely for internal use and not for general
publication or disclosure to any third party. MarketsandMarkets™ does not endorse any vendor, product, or service profiled in its publications. MarketsandMarkets’™ strategic analysis constitutes estimations and projections based on
secondary and primary research and are therefore subject to variations. MarketsandMarkets™ disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness, for any
particular purpose. MarketsandMarkets™ takes no responsibility for incorrect information supplied to it by manufacturers or users.
Trademarks, copyrights, and other forms of intellectual property belong to MarketsandMarkets™ or their respective owners and are protected by law. Under no circumstance may any of these be reproduced, copied, or circulated in any
form, without the prior written approval of MarketsandMarkets™ or its owner—as the case may be. No part of this strategic analysis service may be given, lent, resold, or disclosed to any third party, without express permission from
MarketsandMarkets™.
Reproduction and/or transmission in any form and by any means, including photocopying, mechanical, electronic, recording, or otherwise, without the permission of MarketsandMarkets™, is prohibited.

US OFFICE ASIAN INTELLIGENCE CENTER

© 2020 MarketsandMarkets | www.marketsandmarkets.com 17